Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial.
about
Guidance of Signaling Activations by Cadherins and Integrins in Epithelial Ovarian Cancer CellsGliadel wafer implantation combined with standard radiotherapy and concurrent followed by adjuvant temozolomide for treatment of newly diagnosed high-grade glioma: a systematic literature reviewMolecular Imaging of Angiogenesis and Vascular Remodeling in Cardiovascular PathologyAntiangiogenic mechanisms and factors in breast cancer treatmentImmune Checkpoint Modulators: An Emerging Antiglioma ArmamentariumConcurrent therapy to enhance radiotherapeutic outcomes in glioblastomaAdvances in the treatment of newly diagnosed glioblastomaTherapeutic approach beyond conventional temozolomide for newly diagnosed glioblastoma: Review of the present evidence and future directionβ1 Integrins as Therapeutic Targets to Disrupt Hallmarks of CancerAnti-angiogenic alternatives to VEGF blockadeDevelopment of targeted therapies in treatment of glioblastomaConsensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trialsTension in CancerIntegrins in the Spotlight of CancerTherapeutic Potential of Curcumin for the Treatment of Brain TumorsThe complexity of integrins in cancer and new scopes for therapeutic targetingTumor treating fields: a novel treatment modality and its use in brain tumorsAnti-thrombotic agents derived from snake venom proteinsIndian data on central nervous tumors: A summary of published workGlioblastoma multiforme: emerging treatments and stratification markers beyond new drugsWhat next for newly diagnosed glioblastoma?Inhibition of αvβ3 integrin induces loss of cell directionality of oral squamous carcinoma cells (OSCC)How can we develop therapies for glioblastoma more efficiently? Randomized versus single-arm studies.Real-time near-infrared fluorescence imaging using cRGD-ZW800-1 for intraoperative visualization of multiple cancer types.MGMT-Methylated Alleles Are Distributed Heterogeneously Within Glioma Samples Irrespective of IDH Status and Chromosome 10q Deletion.Antitumor activity of 7-O-succinyl macrolactin A tromethamine salt in the mouse glioma model.Integrin αVβ3 silencing sensitizes malignant glioma cells to temozolomide by suppression of homologous recombination repairActin cytoskeleton regulator Arp2/3 complex is required for DLL1 activating Notch1 signaling to maintain the stem cell phenotype of glioma initiating cells.Contribution of the Microenvironmental Niche to Glioblastoma Heterogeneity.RGD-Binding Integrins in Head and Neck Cancers.Regulation of expression of O6-methylguanine-DNA methyltransferase and the treatment of glioblastoma (Review).Peritumoral edema shown by MRI predicts poor clinical outcome in glioblastomaThe challenges and the promise of molecular targeted therapy in malignant gliomas.Tumor angiogenesis in the absence of fibronectin or its cognate integrin receptors.Ultrasmall integrin-targeted silica nanoparticles modulate signaling events and cellular processes in a concentration-dependent manner.Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE studyEx vivo engineered immune organoids for controlled germinal center reactions.MGMT testing allows for personalised therapy in the temozolomide era.Integrin β3 inhibition is a therapeutic strategy for supravalvular aortic stenosis.Impact of waiting time after surgery and overall time of postoperative radiochemotherapy on treatment outcome in glioblastoma multiforme.
P2860
Q26738643-7779796B-553C-4978-8E51-4C616828B248Q26739012-0241D5FC-73A3-462A-AF83-A9A9C684D795Q26747500-51085BCB-3CC5-415C-AA6C-4DA9DF8DEEFDQ26751226-677AF24C-ED57-4811-AE71-96AEFEBAFD2EQ26765459-5ADDB59C-4408-4171-A36F-6C422F1FA936Q26767169-8B2CFB53-ED7A-482B-B731-4FD01B2AFCB7Q26773514-7FF96831-71BF-429A-A2D5-C65ECAA7AA57Q26774717-D6880438-2FEB-49FB-9DB7-B14AC0700B29Q26774789-6DC1E46C-CA22-4F72-AEB4-1EBDDD32A352Q26775947-939DC899-D108-4679-A992-4FA0E8CFA130Q26778787-6F600FD9-2213-4FBB-B9BA-D5F5BD36E7CBQ26801351-DA1DC8FB-8C0E-49B6-AA9D-6ABC5AAAE770Q28066437-C1AB88AF-D14F-4314-BC47-909F7468B898Q28066805-7EB87870-01EC-458F-A798-1EE141F312A8Q28071572-E388787E-ACBD-41F9-B84C-B33037954C25Q28073343-5EEC4882-D320-482E-A637-31BB7C78AF31Q28073779-85A24B76-E22C-436A-8A11-065EC02A3DCEQ28074523-5818D7E2-243A-414C-91CE-95F8B14195BAQ28079423-95FA258F-E4C7-4091-BB7E-71EA5A96C7D5Q28082603-768F0E22-C259-4D71-AC31-FFD397BF888FQ28086839-788A2F4E-8B3F-4302-860D-C27401EE5D77Q30252508-675639F6-F276-4A56-B8A0-99F5447A2023Q30252700-F42A28C3-9769-47E6-A441-04143D2E0022Q33591441-6C805E08-E39A-40DF-AD26-9107A02EA714Q33615176-0D44CDD8-DACE-4C58-9256-E279460955FCQ33685664-CBCAC3C7-500B-4F3E-930B-F832AE63CB6AQ33709432-0D0922C9-77BD-4CD6-AD36-7D98F6851073Q33779474-34E023E1-B070-4AE8-9AC0-2534169EB103Q33786677-93BD9ECF-11FF-4911-9204-1323E8573BB7Q33832735-87D74D7C-14FE-439F-BE9D-E1DBCE0D4B72Q34478948-6DB21DE7-B9CF-4D06-AF74-32AEA9D057C2Q35174861-E978A9CF-29C2-4087-A224-5F33A7A98BC6Q35214534-ED087453-453C-4846-831E-AA22A75461F0Q35217119-3DCA84D3-47E9-40FB-9E28-90A95074B656Q35562019-45DD3356-171B-410D-A449-4256E8DCF5C5Q35788615-2C3BA33C-DF28-410B-9B5D-0AB3ECC81FE5Q35812007-804F6B76-7C99-48CA-BFF1-DEE6971D4081Q35827916-E038F13B-B812-4CAC-B39E-93F14407CAD2Q35917857-5F640C38-7701-4B76-8BC6-1D0CEDE7F2FEQ36010006-F8B55CC0-9FBE-41D8-97ED-53CF35DD14BD
P2860
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial.
description
2014 nî lūn-bûn
@nan
2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Cilengitide combined with stan ...... ed, open-label, phase 3 trial.
@ast
Cilengitide combined with stan ...... ed, open-label, phase 3 trial.
@en
type
label
Cilengitide combined with stan ...... ed, open-label, phase 3 trial.
@ast
Cilengitide combined with stan ...... ed, open-label, phase 3 trial.
@en
prefLabel
Cilengitide combined with stan ...... ed, open-label, phase 3 trial.
@ast
Cilengitide combined with stan ...... ed, open-label, phase 3 trial.
@en
P2093
P50
P1433
P1476
Cilengitide combined with stan ...... ed, open-label, phase 3 trial.
@en
P2093
Alba A Brandes
Andriy Markivskyy
Astrid Weyerbrock
Benoit Lhermitte
CENTRIC study team
Canadian Brain Tumor Consortium
Catherine McBain
Chae-Yong Kim
Chiung-Chyi Shen
Christine Hicking
P304
P356
10.1016/S1470-2045(14)70379-1
P577
2014-08-19T00:00:00Z